Natasja van de Pol

Low-Dose Naltrexone in Crohn’s Disease: A Prematurely Terminated Randomized Trial Showing Reduced Fatigue Without Clinical or Endoscopic Benefit

Crohn’s disease (CD) is often refractory to standard therapies, and patients are sometimes reluctant to initiate immunosuppressive therapy, prompting interest in novel treatments such as low-dose naltrexone (LDN). To evaluate the efficacy of LDN for induction of remission in pati...